Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Kamilla W. Miskowiak; Ida Seeberg; Mette B. Jensen; Vicent Balanzá-Martínez; Caterina del Mar Bonnin; Christopher R. Bowie; Andre F. Carvalho; Annemieke Dols; Katie Douglas; Peter Gallagher; Gregor Hasler; Beny Lafer; Kathryn E. Lewandowski; Carlos López-Jaramillo; Anabel Martinez-Aran; Roger S. McIntyre; Richard J. Porter; Scot E. Purdon; Ayal Schaffer; Paul Stokes; Tomiki Sumiyoshi; Ivan J. Torres; Tamsyn E. van Rheenen; Lakshmi N. Yatham; Allan H. Young; Lars V. Kessing; Katherine E. Burdick; Eduard Vieta

doi:https://doi.org/10.1111/bdi.13193

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Kamilla W. Miskowiak, Ida Seeberg, Mette B. Jensen, Vicent Balanzá-Martínez, Caterina del Mar Bonnin, Christopher R. Bowie, Andre F. Carvalho, Annemieke Dols, Katie Douglas, Peter Gallagher, Gregor Hasler, Beny Lafer, Kathryn E. Lewandowski, Carlos López-Jaramillo, Anabel Martinez-Aran, Roger S. McIntyre, Richard J. Porter, Scot E. Purdon, Ayal Schaffer, Paul StokesTomiki Sumiyoshi, Ivan J. Torres, Tamsyn E. van Rheenen, Lakshmi N. Yatham, Allan H. Young, Lars V. Kessing, Katherine E. Burdick, Eduard Vieta

Research output: Contribution to journal › Review article › Academic › peer-review

19 Citations (Scopus)

Abstract

Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations. Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials. Results: We identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking. Conclusions: Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.

Original language	English
Pages (from-to)	354-374
Number of pages	21
Journal	Bipolar disorders
Volume	24
Issue number	4
Early online date	2022
DOIs	https://doi.org/10.1111/bdi.13193
Publication status	Published - Jun 2022

Keywords

ISBD Task Force
bipolar disorder
cognitive impairment
intervention
major depressive disorder
randomised controlled trials
recommendations
systematic review

Access to Document

https://doi.org/10.1111/bdi.13193

Cite this

Miskowiak, K. W., Seeberg, I., Jensen, M. B., Balanzá-Martínez, V., del Mar Bonnin, C., Bowie, C. R., Carvalho, A. F., Dols, A., Douglas, K., Gallagher, P., Hasler, G., Lafer, B., Lewandowski, K. E., López-Jaramillo, C., Martinez-Aran, A., McIntyre, R. S., Porter, R. J., Purdon, S. E., Schaffer, A., ... Vieta, E. (2022). Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar disorders, 24(4), 354-374. https://doi.org/10.1111/bdi.13193

@article{7d69633f03fc4894acef0611c3cd3ee4,

title = "Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force",

abstract = "Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations. Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials. Results: We identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking. Conclusions: Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.",

keywords = "ISBD Task Force, bipolar disorder, cognitive impairment, intervention, major depressive disorder, randomised controlled trials, recommendations, systematic review",

author = "Miskowiak, {Kamilla W.} and Ida Seeberg and Jensen, {Mette B.} and Vicent Balanz{\'a}-Mart{\'i}nez and {del Mar Bonnin}, Caterina and Bowie, {Christopher R.} and Carvalho, {Andre F.} and Annemieke Dols and Katie Douglas and Peter Gallagher and Gregor Hasler and Beny Lafer and Lewandowski, {Kathryn E.} and Carlos L{\'o}pez-Jaramillo and Anabel Martinez-Aran and McIntyre, {Roger S.} and Porter, {Richard J.} and Purdon, {Scot E.} and Ayal Schaffer and Paul Stokes and Tomiki Sumiyoshi and Torres, {Ivan J.} and {van Rheenen}, {Tamsyn E.} and Yatham, {Lakshmi N.} and Young, {Allan H.} and Kessing, {Lars V.} and Burdick, {Katherine E.} and Eduard Vieta",

note = "Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non‐funded. KWM holds a 5‐year Lundbeck Foundation Fellowship (grant no. R215‐2015‐4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co‐financed by the ISCIII‐Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d{\textquoteright}Universitats i Recerca del Departament d{\textquoteright}Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non-funded. KWM holds a 5-year Lundbeck Foundation Fellowship (grant no. R215-2015-4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirecci{\'o}n General de Evaluaci{\'o}n and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d{\textquoteright}Universitats i Recerca del Departament d{\textquoteright}Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: KWM has received consultancy fees from Janssen and Lundbeck in the past 3 years. RP uses computer software at no cost for research – provided by SBT‐pro and has received support for travel to educational meetings from Servier and Lundbeck. AS has received advisory or speaking fees from AbbVie, Janssen, Lundbeck, Otsuka and Sunovion in the past 3 years. KD uses computer software at no cost for research provided by SBT‐pro. LVK has received consultancy fees from Lundbeck and Teva in the past 3 years. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi‐Aventis, Sunovion, Takeda, all them unrelated to the present work. VBM has been a consultant, advisor or Continuing Medical Education (CME) speaker over the last 3 years for the following companies: Angelini, Lundbeck, Nutrici{\'o}n M{\'e}dica and Otsuka. AY has conducted paid lectures and advisory boards for Allergan, AstraZeneca, Bionomics, BrainCells Inc., Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Otsuka Pharmaceutical Co., Pharmaceutica, Pfizer, Roche, Sanofi‐Aventis, Servier Laboratories, Sunovion and Wyeth. He was lead Investigator for the EMBOLDEN Study (AstraZeneca), BCI Neuroplasticity Study and Aripiprazole Mania Study, and has been involved in investigator‐initiated studies for AstraZeneca, Eli Lilly and Wyeth. PS reports grants and non‐financial support from Corcept Therapeutics, non‐financial support from Janssen Research and Development LLC, grant funding from Lundbeck and personal fees from Frontiers in Psychiatry and Allergan outside the submitted work. IJT has received has served as consultant for Lundbeck Canada, Sumitomo Dainippon and Community Living British Columbia. LNY has been on speaker/advisory boards for, or has received research grants from Alkermes, Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Dainippon Sumitomo Pharma, GSK, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sanofi, Sunovion and Teva. RM has received personal fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra‐Cellular, Abbvie and Eisai and is a shareholder in the 420 Company and CEO of Champignon. AD, AC, BL, IS, MBJ, CRB, CMB, KEL, PG, CLJ, AMA, SEP, TS and TVR report no conflict of interest. Publisher Copyright: {\textcopyright} 2022 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.",

year = "2022",

month = jun,

doi = "https://doi.org/10.1111/bdi.13193",

language = "English",

volume = "24",

pages = "354--374",

journal = "Bipolar disorders",

issn = "1398-5647",

publisher = "Blackwell Munksgaard",

number = "4",

}

Miskowiak, KW, Seeberg, I, Jensen, MB, Balanzá-Martínez, V, del Mar Bonnin, C, Bowie, CR, Carvalho, AF, Dols, A, Douglas, K, Gallagher, P, Hasler, G, Lafer, B, Lewandowski, KE, López-Jaramillo, C, Martinez-Aran, A, McIntyre, RS, Porter, RJ, Purdon, SE, Schaffer, A, Stokes, P, Sumiyoshi, T, Torres, IJ, van Rheenen, TE, Yatham, LN, Young, AH, Kessing, LV, Burdick, KE & Vieta, E 2022, 'Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force', Bipolar disorders, vol. 24, no. 4, pp. 354-374. https://doi.org/10.1111/bdi.13193

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. / Miskowiak, Kamilla W.; Seeberg, Ida; Jensen, Mette B. et al.
In: Bipolar disorders, Vol. 24, No. 4, 06.2022, p. 354-374.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021

T2 - A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

AU - Miskowiak, Kamilla W.

AU - Seeberg, Ida

AU - Jensen, Mette B.

AU - Balanzá-Martínez, Vicent

AU - del Mar Bonnin, Caterina

AU - Bowie, Christopher R.

AU - Carvalho, Andre F.

AU - Dols, Annemieke

AU - Douglas, Katie

AU - Gallagher, Peter

AU - Hasler, Gregor

AU - Lafer, Beny

AU - Lewandowski, Kathryn E.

AU - López-Jaramillo, Carlos

AU - Martinez-Aran, Anabel

AU - McIntyre, Roger S.

AU - Porter, Richard J.

AU - Purdon, Scot E.

AU - Schaffer, Ayal

AU - Stokes, Paul

AU - Sumiyoshi, Tomiki

AU - Torres, Ivan J.

AU - van Rheenen, Tamsyn E.

AU - Yatham, Lakshmi N.

AU - Young, Allan H.

AU - Kessing, Lars V.

AU - Burdick, Katherine E.

AU - Vieta, Eduard

N1 - Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non‐funded. KWM holds a 5‐year Lundbeck Foundation Fellowship (grant no. R215‐2015‐4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co‐financed by the ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non-funded. KWM holds a 5-year Lundbeck Foundation Fellowship (grant no. R215-2015-4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I+D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: KWM has received consultancy fees from Janssen and Lundbeck in the past 3 years. RP uses computer software at no cost for research – provided by SBT‐pro and has received support for travel to educational meetings from Servier and Lundbeck. AS has received advisory or speaking fees from AbbVie, Janssen, Lundbeck, Otsuka and Sunovion in the past 3 years. KD uses computer software at no cost for research provided by SBT‐pro. LVK has received consultancy fees from Lundbeck and Teva in the past 3 years. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi‐Aventis, Sunovion, Takeda, all them unrelated to the present work. VBM has been a consultant, advisor or Continuing Medical Education (CME) speaker over the last 3 years for the following companies: Angelini, Lundbeck, Nutrición Médica and Otsuka. AY has conducted paid lectures and advisory boards for Allergan, AstraZeneca, Bionomics, BrainCells Inc., Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Otsuka Pharmaceutical Co., Pharmaceutica, Pfizer, Roche, Sanofi‐Aventis, Servier Laboratories, Sunovion and Wyeth. He was lead Investigator for the EMBOLDEN Study (AstraZeneca), BCI Neuroplasticity Study and Aripiprazole Mania Study, and has been involved in investigator‐initiated studies for AstraZeneca, Eli Lilly and Wyeth. PS reports grants and non‐financial support from Corcept Therapeutics, non‐financial support from Janssen Research and Development LLC, grant funding from Lundbeck and personal fees from Frontiers in Psychiatry and Allergan outside the submitted work. IJT has received has served as consultant for Lundbeck Canada, Sumitomo Dainippon and Community Living British Columbia. LNY has been on speaker/advisory boards for, or has received research grants from Alkermes, Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Dainippon Sumitomo Pharma, GSK, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sanofi, Sunovion and Teva. RM has received personal fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra‐Cellular, Abbvie and Eisai and is a shareholder in the 420 Company and CEO of Champignon. AD, AC, BL, IS, MBJ, CRB, CMB, KEL, PG, CLJ, AMA, SEP, TS and TVR report no conflict of interest. Publisher Copyright: © 2022 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.

PY - 2022/6

Y1 - 2022/6

N2 - Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations. Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials. Results: We identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking. Conclusions: Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.

AB - Background: Cognitive impairments are an emerging treatment target in mood disorders, but currently there are no evidence-based pro-cognitive treatments indicated for patients in remission. With this systematic review of randomised controlled trials (RCTs), the International Society for Bipolar Disorders (ISBD) Targeting Cognition Task force provides an update of the most promising treatments and methodological recommendations. Methods: The review included RCTs of candidate pro-cognitive interventions in fully or partially remitted patients with major depressive disorder or bipolar disorder. We followed the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE and Cochrane Library from January 2015, when two prior systematic reviews were conducted, until February 2021. Two independent authors reviewed the studies with the Revised Cochrane Collaboration's Risk of Bias tool for Randomised trials. Results: We identified 16 RCTs (N = 859) investigating cognitive remediation (CR; k = 6; N = 311), direct current or repetitive magnetic stimulation (k = 3; N = 127), or pharmacological interventions (k = 7; N = 421). CR showed most consistent cognitive benefits, with two trials showing improvements on primary outcomes. Neuromodulatory interventions revealed no clear efficacy. Among pharmacological interventions, modafinil and lurasidone showed early positive results. Sources of bias included small samples, lack of pre-screening for objective cognitive impairment, no primary outcome and no information on allocation sequence masking. Conclusions: Evidence for pro-cognitive treatments in mood disorders is emerging. Recommendations are to increase sample sizes, pre-screen for impairment in targeted domain(s), select one primary outcome, aid transfer to real-world functioning, investigate multimodal interventions and include neuroimaging.

KW - ISBD Task Force

KW - bipolar disorder

KW - cognitive impairment

KW - intervention

KW - major depressive disorder

KW - randomised controlled trials

KW - recommendations

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85125096932&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/bdi.13193

DO - https://doi.org/10.1111/bdi.13193

M3 - Review article

C2 - 35174594

SN - 1398-5647

VL - 24

SP - 354

EP - 374

JO - Bipolar disorders

JF - Bipolar disorders

IS - 4

ER -

Miskowiak KW, Seeberg I, Jensen MB, Balanzá-Martínez V, del Mar Bonnin C, Bowie CR et al. Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar disorders. 2022 Jun;24(4):354-374. Epub 2022. doi: https://doi.org/10.1111/bdi.13193

Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force

Abstract

Keywords

Access to Document

Other files and links

Cite this